(ALC) Alcon - Ratings and Ratios
Cataract Equipment, IOL Lenses, Femtosecond Laser, Contact Lenses, Eye Drops
ALC EPS (Earnings per Share)
ALC Revenue
Description: ALC Alcon
Alcon AG (NYSE:ALC) is a global leader in the eye care industry, operating through two main segments: Surgical and Vision Care. The companys product portfolio includes a wide range of innovative solutions for cataract surgery, vitreoretinal surgery, and refractive surgery, as well as contact lenses and ocular health products.
From a business perspective, Alcons Surgical segment is a significant contributor, with a strong lineup of products such as intraocular lenses (IOLs), viscoelastics, and surgical instrumentation. The companys cataract products, including the Centurion vision system and LenSx laser system, are highly regarded in the industry. Additionally, Alcons vision care segment offers a variety of contact lenses, including daily disposables and color-enhancing lenses, as well as ocular health products for dry eye, ocular allergies, and glaucoma.
To evaluate Alcons performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating margin are crucial. With a market capitalization of $43.5 billion, Alcons financials indicate a significant presence in the healthcare equipment industry. The companys return on equity (RoE) of 5.25% suggests a relatively modest return, potentially indicating room for improvement in profitability. Furthermore, the price-to-earnings (P/E) ratio of 39.01 and forward P/E of 27.70 imply that the stock may be trading at a premium, warranting closer examination of the companys growth prospects and competitive positioning.
From a competitive standpoint, Alcon operates in a highly competitive market with other major players such as Johnson & Johnson Vision and Bausch + Lomb. To maintain its market share, Alcon must continue to innovate and expand its product portfolio, while also optimizing its operational efficiency and managing costs effectively. By monitoring KPIs such as research and development (R&D) expenses as a percentage of revenue, Alcons commitment to innovation can be assessed.
ALC Stock Overview
| Market Cap in USD | 39,522m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2019-04-09 |
ALC Stock Ratings
| Growth Rating | 7.77% |
| Fundamental | 59.3% |
| Dividend Rating | 51.1% |
| Return 12m vs S&P 500 | -33.5% |
| Analyst Rating | 4.33 of 5 |
ALC Dividends
| Dividend Yield 12m | 0.40% |
| Yield on Cost 5y | 0.58% |
| Annual Growth 5y | 5.89% |
| Payout Consistency | 99.5% |
| Payout Ratio | 11.0% |
ALC Growth Ratios
| Growth Correlation 3m | -62.1% |
| Growth Correlation 12m | -44% |
| Growth Correlation 5y | 72.3% |
| CAGR 5y | 6.39% |
| CAGR/Max DD 3y | 0.28 |
| CAGR/Mean DD 3y | 0.82 |
| Sharpe Ratio 12m | -0.05 |
| Alpha | 0.00 |
| Beta | 0.976 |
| Volatility | 32.02% |
| Current Volume | 1407.7k |
| Average Volume 20d | 2066k |
| Stop Loss | 75.3 (-3%) |
| Signal | -0.36 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (1.07b TTM) > 0 and > 6% of Revenue (6% = 601.5m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 1.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 38.72% (prev 37.85%; Δ 0.88pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 2.06b > Net Income 1.07b (YES >=105%, WARN >=100%) |
| Net Debt (3.84b) to EBITDA (1.38b) ratio: 2.79 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.60 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (497.9m) change vs 12m ago 0.18% (target <= -2.0% for YES) |
| Gross Margin 55.13% (prev 55.37%; Δ -0.23pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 32.81% (prev 32.42%; Δ 0.39pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.79 (EBITDA TTM 1.38b / Interest Expense TTM 197.8m) >= 6 (WARN >= 3) |
Altman Z'' 5.49
| (A) 0.12 = (Total Current Assets 6.31b - Total Current Liabilities 2.42b) / Total Assets 31.39b |
| (B) 0.62 = Retained Earnings (Balance) 19.36b / Total Assets 31.39b |
| (C) 0.02 = EBIT TTM 749.7m / Avg Total Assets 30.55b |
| (D) 2.39 = Book Value of Equity 22.11b / Total Liabilities 9.26b |
| Total Rating: 5.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 59.26
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 3.72% = 1.86 |
| 3. FCF Margin 15.94% = 3.99 |
| 4. Debt/Equity 0.22 = 2.48 |
| 5. Debt/Ebitda 3.49 = -2.30 |
| 6. ROIC - WACC (= -6.37)% = -7.97 |
| 7. RoE 4.93% = 0.41 |
| 8. Rev. Trend 88.85% = 6.66 |
| 9. EPS Trend 72.59% = 3.63 |
What is the price of ALC shares?
Over the past week, the price has changed by -1.58%, over one month by -11.90%, over three months by -9.93% and over the past year by -20.99%.
Is Alcon a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALC is around 66.51 USD . This means that ALC is currently overvalued and has a potential downside of -14.34%.
Is ALC a buy, sell or hold?
- Strong Buy: 15
- Buy: 6
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ALC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 97.6 | 25.7% |
| Analysts Target Price | 97.6 | 25.7% |
| ValueRay Target Price | 74.3 | -4.3% |
Last update: 2025-09-03 02:50
ALC Fundamental Data Overview
CCE Cash And Equivalents = 1.41b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 36.9491
P/E Forward = 25.7732
P/S = 3.9424
P/B = 1.7843
P/EG = 2.1641
Beta = 0.692
Revenue TTM = 10.03b USD
EBIT TTM = 749.7m USD
EBITDA TTM = 1.38b USD
Long Term Debt = 4.66b USD (from longTermDebt, last quarter)
Short Term Debt = 147.0m USD (from shortTermDebt, last quarter)
Debt = 4.81b USD (Calculated: Short Term 147.0m + Long Term 4.66b)
Net Debt = 3.84b USD (from netDebt column, last quarter)
Enterprise Value = 42.93b USD (39.52b + Debt 4.81b - CCE 1.41b)
Interest Coverage Ratio = 3.79 (Ebit TTM 749.7m / Interest Expense TTM 197.8m)
FCF Yield = 3.72% (FCF TTM 1.60b / Enterprise Value 42.93b)
FCF Margin = 15.94% (FCF TTM 1.60b / Revenue TTM 10.03b)
Net Margin = 10.70% (Net Income TTM 1.07b / Revenue TTM 10.03b)
Gross Margin = 55.13% ((Revenue TTM 10.03b - Cost of Revenue TTM 4.50b) / Revenue TTM)
Tobins Q-Ratio = 1.94 (Enterprise Value 42.93b / Book Value Of Equity 22.11b)
Interest Expense / Debt = 1.06% (Interest Expense 51.0m / Debt 4.81b)
Taxrate = 18.95% (238.0m / 1.26b)
NOPAT = 607.6m (EBIT 749.7m * (1 - 18.95%))
Current Ratio = 2.60 (Total Current Assets 6.31b / Total Current Liabilities 2.42b)
Debt / Equity = 0.22 (Debt 4.81b / last Quarter total Stockholder Equity 22.11b)
Debt / EBITDA = 3.49 (Net Debt 3.84b / EBITDA 1.38b)
Debt / FCF = 3.01 (Debt 4.81b / FCF TTM 1.60b)
Total Stockholder Equity = 21.76b (last 4 quarters mean)
RoA = 3.42% (Net Income 1.07b, Total Assets 31.39b )
RoE = 4.93% (Net Income TTM 1.07b / Total Stockholder Equity 21.76b)
RoCE = 2.84% (Ebit 749.7m / (Equity 21.76b + L.T.Debt 4.66b))
RoIC = 2.29% (NOPAT 607.6m / Invested Capital 26.58b)
WACC = 8.66% (E(39.52b)/V(44.33b) * Re(9.61%)) + (D(4.81b)/V(44.33b) * Rd(1.06%) * (1-Tc(0.19)))
Shares Correlation 3-Years: 78.79 | Cagr: 0.06%
Discount Rate = 9.61% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.52% ; FCFE base≈1.39b ; Y1≈1.72b ; Y5≈2.93b
Fair Price DCF = 76.25 (DCF Value 37.70b / Shares Outstanding 494.4m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 72.59 | EPS CAGR: 16.45% | SUE: 1.74 | # QB: 1
Revenue Correlation: 88.85 | Revenue CAGR: 7.28% | SUE: N/A | # QB: None
Additional Sources for ALC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle